AngioDynamics, Inc. provided earnings guidance for the fiscal year 2024. For the fiscal year 2024, the company now expects its fiscal year 2024 net sales to be in the range of $320 million to $325 million, accounting for the softer Thrombectomy sales during the fiscal second quarter, which it now expects will continue throughout the back half of the year, as well as certain SKU rationalization and other impacts associated with the manufacturing restructuring.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.81 USD | +0.52% | -7.19% | -25.89% |
Apr. 08 | North American Morning Briefing : Inflation Data, -2- | DJ |
Apr. 05 | Oppenheimer Upgrades AngioDynamics to Outperform From Perform, $12 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.89% | 233M | |
-2.31% | 187B | |
-3.20% | 106B | |
-5.04% | 66.9B | |
+0.20% | 49.45B | |
+17.29% | 48B | |
+4.06% | 40.84B | |
+2.07% | 26.48B | |
+2.36% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- ANGO Stock
- News AngioDynamics, Inc.
- AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2024